Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Portfolio Pulse from
Affimed N.V. reported promising Phase 1 results for its drug AFM28 in treating relapsed/refractory acute myeloid leukemia, showing clinical efficacy and a manageable safety profile.

December 09, 2024 | 6:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed N.V. announced promising Phase 1 results for AFM28 in treating relapsed/refractory acute myeloid leukemia, indicating potential efficacy and safety.
The announcement of promising Phase 1 results for AFM28 in treating R/R AML is likely to positively impact Affimed's stock price. The data suggests potential efficacy and safety, which is crucial for further development and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100